Screener
Oruka Therapeutics, Inc. ORKA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development(1) | $29,145 | $19,925 |
| General and administrative(2) | 7,289 | 5,161 |
| Total operating expenses | 36,434 | 25,086 |
| Loss from operations | (36,434) | (25,086) |
| Other income (expense): | ||
| Interest income | 4,606 | 4,092 |
| Other income (expense), net | 8 | (5) |
| Total other income, net | 4,614 | 4,087 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s operating income?
- Oruka Therapeutics, Inc. (ORKA) reported operating income of -$36.43M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s operating income changed year-over-year?
- Oruka Therapeutics, Inc.'s operating income decreased by 45.2% year-over-year, from -$25.09M to -$36.43M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s operating income has grown at a 58.5% compound annual growth rate (CAGR), from -$19.34M to -$122.05M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Oruka Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude